Keywords: corporate, year-end, results, round-up, bio-technology, general, corp
US Corporate 1997 Year-End Results Round-Up
Article | 11 February 1998
Bio-Technology General Corp said that pretax income for 1997 was $21.2million, almost double last year's figure, while revenues grew 37% to $65.3 million, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
